For most of medical history, treatment has been designed for the average patient. A drug is tested on thousands of volunteers, and if it helps enough of them without causing serious harm, it is approved for everyone with the same condition. This approach has saved countless lives, but it has an obvious flaw: none of us is average. Two people with the same diagnosis may respond to the same medicine in completely different ways, and one of them may suffer side effects that the other never experiences.
Precision medicine, sometimes called personalised medicine, aims to address this problem by tailoring prevention and treatment to the individual. It takes into account a person's genes, environment and lifestyle, and its rise has been driven above all by advances in genetics. When the first human genome was sequenced in the early 2000s, the project had taken over a decade and cost billions of dollars. Today the same task can be completed in a matter of days at a tiny fraction of the cost.
Cancer care offers the clearest examples of what this can mean in practice. Tumours were traditionally classified by where they appeared in the body, but doctors now know that cancers in the same organ can be driven by different genetic changes. By testing a tumour, specialists can sometimes identify a specific mutation and choose a so-called targeted drug designed to act on it, sparing patients treatments that would be unlikely to work. Genetic information can also predict how quickly a person's body will break down certain medicines, helping doctors to set a safer dose from the start, rather than by trial and error.
Dr Lena Hartmann, a clinical geneticist at a hospital in Leeds, describes the change as 'a shift from asking which disease a patient has to asking which version of it they have'. She is, however, careful not to overstate what has been achieved. 'For a handful of conditions, the benefits are real and well established,' she says. 'For many others, we are still at the stage of promising research.'
Her caution reflects several genuine challenges. Most common illnesses, such as heart disease or type 2 diabetes, are influenced by hundreds of genes, each with a small effect, as well as by diet, exercise and living conditions. Knowing someone's genetic profile may therefore tell us rather less than headlines suggest. There is also the question of fairness. Much of the genetic data collected so far comes from people of European ancestry, which means that some tests may be less accurate for everyone else. Researchers around the world are now working to build more diverse databases, but closing the gap will take time.
Then there are questions of cost and privacy. Targeted drugs can be extremely expensive, and health systems with limited budgets must decide whether the benefit to a relatively small group of patients justifies the price. Meanwhile, genetic data is uniquely personal: it cannot be changed like a password, and it reveals information not only about an individual but about their relatives. Strong rules on who may access such data, and for what purpose, are widely seen as essential if the public is to trust the system.
None of this means that precision medicine is mere hype. Rather, it suggests that its progress is likely to be gradual, uneven and dependent on decisions that are as much ethical and economic as scientific. As Dr Hartmann puts it, 'The technology is racing ahead. The harder part is making sure it reaches everyone who could benefit, and that patients understand what their results do and do not mean.' Anyone curious about genetic testing, she adds, should talk to their doctor first rather than relying on tests bought online, whose results can be difficult to interpret.